{"id":343,"date":"2024-11-08T09:50:11","date_gmt":"2024-11-08T09:50:11","guid":{"rendered":"https:\/\/admit:8890\/news\/"},"modified":"2025-05-10T10:27:04","modified_gmt":"2025-05-10T10:27:04","slug":"news","status":"publish","type":"page","link":"https:\/\/admit-therapeutics.com\/en\/news\/","title":{"rendered":"News"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\">News<\/h1>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"wp-block-query is-layout-flow wp-block-query-is-layout-flow\">\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\"><ul class=\"columns-3 wp-block-post-template is-layout-grid wp-container-core-post-template-is-layout-50eac3a5 wp-block-post-template-is-layout-grid\"><li class=\"wp-block-post post-1538 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-presents-the-map-ad-test-at-the-13th-argentine-congress-of-clinical-laboratory-quality-calilab-2026\/\" target=\"_self\" >ADmit Therapeutics presents the MAP-AD\u00a0Test at the 13th Argentine Congress of Clinical Laboratory Quality (CALILAB 2026)<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona (Spain), November 4, 2026. ADmit Therapeutics will participate in the Neurogenetics Conference organized by MANLAB within the framework of the 13th Argentine Congress of Clinical Laboratory Quality (CALILAB 2026).\u00a0Dr.\u00a0Carla Trapero will present the MAP-AD Test,\u00a0the only regulatory-approved blood-based prognostic test (IVDR &#8211; EU 2017\/746) that predicts progression to Alzheimer\u2019s dementia in patients with mild&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-presents-the-map-ad-test-at-the-13th-argentine-congress-of-clinical-laboratory-quality-calilab-2026\/\">Read more<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1523 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/en\/pioneering-precision-medicine-for-alzheimers-viacare-and-admit-therapeutics-partner-to-transform-patient-centered-neurological-care\/\" target=\"_self\" >Pioneering Precision Medicine for Alzheimer&#8217;s: ViaCare and ADmit Therapeutics Partner to Transform Patient-Centered Neurological Care<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona (Spain), October 21, 2026. Faced with Alzheimer&#8217;s disease, a pathology that deeply affects not only those living with it, but also their families and loved ones, early clarity and personal, compassionate, and close orientation are essential.\u00a0ViaCare, a leading comprehensive private medical center in Madrid belonging to the\u00a0Viamed Salud Group, and\u00a0ADmit\u00a0Therapeutics, a Spanish biotechnology company&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/en\/pioneering-precision-medicine-for-alzheimers-viacare-and-admit-therapeutics-partner-to-transform-patient-centered-neurological-care\/\">Read more<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1481 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-closes-strategic-agreement-with-hvd-life-sciences-to-accelerate-commercial-expansion\/\" target=\"_self\" >ADmit Therapeutics Closes Strategic Agreement with HVD Life Sciences to Accelerate Commercial Expansion<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona (Spain), September 15, 2026. ADmit\u00a0Therapeutics, a biotechnology company specializing in innovative diagnostic solutions for neurodegenerative diseases, is pleased to announce a new collaboration with\u00a0HVD Life Sciences, a recognized leader in the commercialization of\u00a0in vitro\u00a0diagnostic solutions across international markets. This agreement represents a key milestone in ADmit Therapeutics&#8217; commercial expansion strategy.&nbsp;HVD Life Sciences&#8216; deep expertise&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-closes-strategic-agreement-with-hvd-life-sciences-to-accelerate-commercial-expansion\/\">Read more<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1410 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-obtains-clia-certification-opening-doors-to-the-u-s-healthcare-market\/\" target=\"_self\" >ADmit Therapeutics Obtains CLIA Certification, Opening Doors to the U.S. Healthcare Market<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona (Spain), December\u00a04, 2025. ADmit Therapeutics today announced that it has obtained the\u00a0CLIA (Clinical Laboratory Improvement Amendments) Certificate. This accreditation, granted by the US Centers for Medicare &amp; Medicaid Services (CMS), confirms compliance with the most\u00a0stringent standards for analytical quality and reliability. Obtaining CLIA certification is a crucial milestone that transforms ADmit Therapeutics into a&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-obtains-clia-certification-opening-doors-to-the-u-s-healthcare-market\/\">Read more<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1388 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-presents-innovation-in-seville-the-map-ad-test-and-new-data-on-alzheimers-prediction\/\" target=\"_self\" >ADmit Therapeutics Presents Innovation in Seville: The MAP-AD\u00ae\u00a0Test and New Data on Alzheimer&#8217;s Prediction<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">The company will attend the SEN Annual Meeting with its MAP-AD\u00ae&nbsp;test, recently certified with the CE-IVDR mark, highlighting breakthroughs in early Alzheimer&#8217;s disease dementia prognosis. Barcelona (Spain), November 14, 2025\u00a0\u2013 ADmit Therapeutics, a leading company in the diagnosis of neurodegenerative diseases, has confirmed its participation in the upcoming\u00a0Annual Meeting of the Spanish Society of Neurology&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-presents-innovation-in-seville-the-map-ad-test-and-new-data-on-alzheimers-prediction\/\">Read more<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1364 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-to-showcase-european-innovation-at-medica-2025\/\" target=\"_self\" >ADmit Therapeutics to showcase European innovation at MEDICA 2025<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona (Spain), November 13,2025. We are proud to announce that our company has been selected to participate in MEDICA 2025, taking place from 17\u201320 November 2025 in D\u00fcsseldorf, Germany. ADmit Therapeutis will be at the EIC Pavilion at Messe D\u00fcsseldorf \u2013 Hall 15, Booth 15B41. Our company is one of the 15 SMEs, start-ups, and&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-to-showcase-european-innovation-at-medica-2025\/\">Read more<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><\/ul><\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>News<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-343","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/pages\/343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/comments?post=343"}],"version-history":[{"count":6,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/pages\/343\/revisions"}],"predecessor-version":[{"id":1014,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/pages\/343\/revisions\/1014"}],"wp:attachment":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/media?parent=343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}